Drug Profile

EN 374

Alternative Names: EN-374

Latest Information Update: 21 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ensoma
Class Gene therapies; Stem cell therapies
Mechanism of Action Gene transference; NADPH oxidase 2 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Chronic granulomatous disease
New Molecular Entity No

Highest Development Phases

Preclinical Chronic granulomatous disease

Most Recent Events

12 May 2025 US FDA clears the investigational new drug (IND) application for EN 374 in Chronic granulomatous disease
12 May 2025 Ensoma plans a phase I/II trial for Chronic granulomatous disease (In infants, In children, In adolescents, In adults, In the elderly) in quarter four of 2025 (IV) (NCT06876363)
08 May 2025 9441110: Minor updated in PD data hence separate HE not added.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com